Kimberly-Clark stock gains analyst support as Kenvue deal advances
Published on 09/16/2026 at 15:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kimberly-Clark stock (ISIN US4943681035) is trading at USD 98.68 on Nasdaq as of September 15, 2026, with the shares down 4.13% over the past five days but still supported by solid fundamentals and a pending USD 40 billion acquisition of Kenvue that could reshape the group’s profile.
Strategic Kenvue deal adds scale
According to Yahoo Finance on September 15, 2026, Kimberly-Clark Corporation is preparing asset sales in Europe to address antitrust concerns around its planned USD 40 billion acquisition of consumer-health peer Kenvue, aiming to secure European Commission approval by the September 29, 2026 deadline and avoid an extended four-month probe.
The planned combination is strategically significant because it would create a consumer-health and personal-care company with approximately USD 32 billion in annual revenue and USD 7 billion of adjusted EBITDA, based on the deal presentation figures cited by Yahoo Finance, significantly increasing scale relative to Kimberly-Clark’s existing business.
Valuation, dividend and cash flow context
A deeper look at valuation shows that Kimberly-Clark is not priced as a growth stock despite the Kenvue ambitions. On September 15, 2026, an analysis by GuruFocus estimated a GF Value of USD 123.72 per share versus a then market price of USD 97.39, implying that Kimberly-Clark stock was 21.3% undervalued on that intrinsic value metric.
The same GuruFocus report highlighted a dividend yield of 5.23% and a payout ratio of 89%, pointing out that while the yield is attractive for income-focused investors, the high payout relative to earnings raises questions about long-term sustainability even though the company has delivered modest average dividend growth of about 2.8% per year over the past three years.
From a cash-flow perspective, an overview on Simply Wall St on September 16, 2026 described Kimberly-Clark as potentially undervalued by around the mid-teens percentage range on a discounted cash flow basis, reinforcing the picture that the current share price is below some valuation estimates that factor in steady cash generation.
Analyst ratings point to moderate upside
Analyst sentiment on Kimberly-Clark has become more supportive in mid-September 2026. As The Globe and Mail reported on September 16, 2026, RBC Capital analyst Nik Modi maintained a Buy rating on Kimberly-Clark on September 11 and set a price target of USD 162.00, compared with a closing share price of USD 98.15 at that time, implying potential upside of more than 60% if the target is reached.
In the same coverage, The Globe and Mail noted that Kimberly-Clark has an overall analyst consensus of Moderate Buy with a consensus price target of USD 115.83, representing an 18.01% upside versus the then current level, while Piper Sandler also maintained a Buy rating with a USD 118.00 target in a report released on September 11, 2026.
At the same time, more cautious voices remain. According to a separate note summarized by The Globe and Mail on September 16, 2026, Barclays analyst Lauren Lieberman reaffirmed a Hold rating with a price target of USD 105.00, and Wells Fargo also has the stock at Hold, showing that not all analysts expect dramatic outperformance even if the Kenvue integration proceeds smoothly.
Recent trading and market metrics
Per Nasdaq data cited on MarketWatch, Kimberly-Clark stock last closed at USD 98.68 on September 15, 2026 at 4:00 p.m. Eastern Time, with the shares trading on the U.S. Nasdaq exchange under ticker KMB.
The same MarketWatch overview shows that Kimberly-Clark’s five-day performance stood at minus 4.13%, the one-month change was minus 8.40%, and the year-to-date performance was minus 2.20% as of September 15, 2026, while the one-year return was down 21.09%, indicating that the stock has lagged the broader market over the past year despite the more recent analyst support.
In intraday trading on September 15, 2026, a German-language market report from finanzen.ch noted that Kimberly-Clark shares were down about 1.4% at USD 97.71 at 4:28 p.m. local time, with a session low of USD 97.51 after opening around USD 98.28, underlining that the stock remains volatile around the high-90s level.
Fundamental backdrop ahead of next earnings
For the fundamental picture, investors are already looking ahead to the next quarterly report. The same finanzen.ch piece stated that Kimberly-Clark is expected to present its Q3 2026 figures on October 27, 2026, and consensus estimates point to earnings per share of USD 7.42 for the full year 2026, which investors will compare against the richer valuation implied by the Kenvue transaction.
While detailed quarterly revenue and margin figures from the most recent report are not contained in the week-filtered sources, valuation comments from Yahoo Finance emphasize that the combined entity’s roughly USD 7 billion adjusted EBITDA would increase Kimberly-Clark’s earnings base significantly compared with its standalone profile, and that the deal is designed to strengthen positions in personal care and consumer-health categories where brand strength and scale matter for margins.
Stock level and investor perspective
Against this backdrop, Kimberly-Clark stock closed at USD 98.68 on Nasdaq on September 15, 2026, and that level sits notably below the consensus analyst target of USD 115.83 cited by The Globe and Mail, but above the levels implied by some of the more cautious Hold ratings, leaving investors to weigh the upside potential from the Kenvue integration against dividend sustainability and recent share price underperformance.
Kimberly-Clark stock facts
- Company: Kimberly-Clark Corporation
- ISIN: US4943681035
- Ticker: KMB
- Trading venue: Nasdaq
- Price (as of September 15, 2026, 16:00): 98.68 USD
- Sector / Industry: Consumer staples / Household and personal care
- Index membership: S&P 500
- Next earnings date: October 27, 2026
